These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 16200908)

  • 21. [Safety and tolerability of nicotinic acid. Results of the multicenter, open, prospective NAUTILUS study].
    Vogt A; Kassner U; Hostalek U; Peiter A; Steinhagen-Thiessen E
    MMW Fortschr Med; 2006 May; 148(18):41. PubMed ID: 16736688
    [No Abstract]   [Full Text] [Related]  

  • 22. [Statin and absorption inhibitor work synergistically. More risk patient reach LDL cholesterol goal value].
    MMW Fortschr Med; 2007 Apr; 149(17):56-7. PubMed ID: 17674912
    [No Abstract]   [Full Text] [Related]  

  • 23. Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study).
    LaRosa JC; Grundy SM; Kastelein JJ; Kostis JB; Greten H;
    Am J Cardiol; 2007 Sep; 100(5):747-52. PubMed ID: 17719314
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Advances in the management of hyperlipidemia-induced atherosclerosis.
    Tannock LR
    Expert Rev Cardiovasc Ther; 2008 Mar; 6(3):369-83. PubMed ID: 18327996
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [An extensive English study: reduced cardiovascular mortality and morbidity by statin].
    Nilsson P; Erhardt L
    Lakartidningen; 2001 Dec; 98(51-52):5846-50. PubMed ID: 11806257
    [No Abstract]   [Full Text] [Related]  

  • 26. [Considerable remaining risk in unchecked LDL lowering. Is the HDL increase the way out?].
    MMW Fortschr Med; 2006 Jun; 148(24):6, 8. PubMed ID: 16856232
    [No Abstract]   [Full Text] [Related]  

  • 27. A dose-specific meta-analysis of lipid changes in randomized controlled trials of atorvastatin and simvastatin.
    Rogers SL; Magliano DJ; Levison DB; Webb K; Clarke PJ; Grobler MP; Liew D
    Clin Ther; 2007 Feb; 29(2):242-52. PubMed ID: 17472817
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
    Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
    Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [LDL cholesterol in cardiovascular risk patients should be as low as possible].
    MMW Fortschr Med; 2007 Oct; 149(41):44-5. PubMed ID: 17992793
    [No Abstract]   [Full Text] [Related]  

  • 30. [New lower cholesterol levels--more debate].
    Lindberg M
    Ugeskr Laeger; 2005 Jan; 167(3):307-8; author reply 308-9. PubMed ID: 15704805
    [No Abstract]   [Full Text] [Related]  

  • 31. Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy.
    Pearson TA; Ballantyne CM; Veltri E; Shah A; Bird S; Lin J; Rosenberg E; Tershakovec AM
    Am J Cardiol; 2009 Feb; 103(3):369-74. PubMed ID: 19166691
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Plant stanoles in the prevention of cardiovascular diseases. Requirements regarding hard terminal points of soft margarines].
    Astrup AV; Ovesen LF; Stender S
    Ugeskr Laeger; 2001 Nov; 163(46):6437-9. PubMed ID: 11816923
    [No Abstract]   [Full Text] [Related]  

  • 33. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy.
    Silva M; Matthews ML; Jarvis C; Nolan NM; Belliveau P; Malloy M; Gandhi P
    Clin Ther; 2007 Feb; 29(2):253-60. PubMed ID: 17472818
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B.
    Kastelein JJ; Wedel MK; Baker BF; Su J; Bradley JD; Yu RZ; Chuang E; Graham MJ; Crooke RM
    Circulation; 2006 Oct; 114(16):1729-35. PubMed ID: 17030687
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Sequelae of the JUPITER study. What is changing in primary prevention? (interview by Dr. med. Dirk Einecke)].
    Parhofer K
    MMW Fortschr Med; 2008 Dec; 150(49-50):14. PubMed ID: 19130769
    [No Abstract]   [Full Text] [Related]  

  • 36. A multicentre, open study to assess the effect of individualizing starting doses of atorvastatin according to baseline LDL-C levels on achieving cholesterol targets: the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST-2) study.
    Farsang C; Athyros V; Gaw A;
    Curr Med Res Opin; 2007 Aug; 23(8):1945-56. PubMed ID: 17626713
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Dual cholesterol inhibition. More high risk patients achieve LDL cholesterol values below 100 mg/dl].
    MMW Fortschr Med; 2008 Jun; 150(23):39. PubMed ID: 18575369
    [No Abstract]   [Full Text] [Related]  

  • 38. Lipid-altering drugs: decreasing cardiovascular disease at the expense of increasing cancer?
    Goldstein MR; Murao K; Imachi H; Ishida T; Wong NC
    Cancer Res; 2004 Sep; 64(18):6831; author reply 6831-2. PubMed ID: 15375004
    [No Abstract]   [Full Text] [Related]  

  • 39. Is it appropriate to make statins available over the counter? The argument against the appropriateness of over-the-counter statins.
    Barter PJ; Rye KA
    Circulation; 2006 Sep; 114(12):1315-20; discussion 1320. PubMed ID: 16982953
    [No Abstract]   [Full Text] [Related]  

  • 40. Are we lowering LDL cholesterol sufficiently?
    Barter P; Rye KA
    Nat Clin Pract Cardiovasc Med; 2006 Jun; 3(6):290-1. PubMed ID: 16728988
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.